14M118: Abstracts: Immunological Complications of Medical Therapy (1667–1670)

Abstract Moderator(s)

• 

  Ami Shah, MD

  Johns Hopkins Rheumatology
  Ellicott City, MD, United States

  Disclosure(s): Arena Pharmaceuticals: Grant/Research Support (Ongoing); Eicos Sciences/Medpace: Grant/Research Support (Ongoing); Kadmon Corporation/Medpace: Grant/Research Support (Ongoing)
• 

  Xavier Mariette, MD

  Université Paris-Saclay
  Le Kremlin Bicetre, France

  Disclosure(s): Bristol-Myers Squibb(BMS): Advisor or Review Panel Member (Ongoing); Galapagos: Advisor or Review Panel Member (Ongoing); GlaxoSmithKlein(GSK): Advisor or Review Panel Member (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing); Pfizer: Advisor or Review Panel Member (Ongoing)

Oral abstract session.

Presentations:

• 10:30 AM – 10:40 AM Eastern Time

  Pre-existing Rheumatoid Arthritis Patients Initiating Immune Checkpoint Inhibitors for Cancer Treatment: A Comparative Cohort Study Investigating RA Flare and Mortality
  

  Presenting Author: Kaitlin McCarter, MD – Brigham and Women's Hospital
• 10:40 AM – 10:45 AM Eastern Time

  Q&A
  
• 10:45 AM – 10:55 AM Eastern Time

  Rheumatic Toxicities of Immune Checkpoint Inhibitors Predict Favourable Tumour Responses in Patients with Advanced Melanoma
  

  Presenting Author: Alana Bruce, MBBS – Macquarie University
• 10:55 AM – 11:00 AM Eastern Time

  Q&A
  
• 11:00 AM – 11:10 AM Eastern Time

  Comparing the Safety and Effectiveness of Methotrexate, TNF and IL6 Inhibitors for the Treatment of Checkpoint Inhibitor Arthritis
  

  Presenting Author: Anne Bass, MD – Hospital for Special Surgery, Weill Cornell Medicine
• 11:10 AM – 11:15 AM Eastern Time

  Q&A
  
• 11:15 AM – 11:25 AM Eastern Time

  Phase II Clinical Trial to Assess the Safety and Efficacy of Tocilizumab in Combination with Ipilimumab and Nivolumab for Treatment-naïve Metastatic Melanoma
  

  Presenting Author: Noha Abdel-Wahab, MD, PhD – University of Texas MD Anderson Cancer Center
• 11:25 AM – 11:30 AM Eastern Time

  Q&A